ALE-26015 organic compound: AXB began Phase I testing

Allelix Biopharmaceuticals Inc. (TSE:AXB), Mississauga, Ontario Product: ALE-26015 organic compound Indication: Treat dementia in patients with Alzheimer's disease Status: AXB began Phase I testing o...